Integrative Genomics and Bioinformatics Core Shared Resource ABSTRACT The Integrative Genomics and Bioinformatics Core (IGBC) combines the expertise and instrumentation of two NCI-supported facilities?the Functional Genomics/Genomic Sequencing Core and the Bioinformatics Core?to provide an integrated array of services for genomics and informatics. The overall goal of the IGBC is to provide comprehensive genomic and bioinformatics services to City of Hope Comprehensive Cancer Center (COHCCC) investigators. The IGBC accomplishes this goal using state-of-the-art genome technologies and innovative analytical methods supported by a dedicated team of instrument operators and bioinformaticians. The IGBC is equipped with major instrumentation for genomic analyses, including an Illumina Hiseq2500 sequencer, an Illumina miSeq sequencer, a PacBio RSII sequencer, a Fluidigm C1, a 10X Genomics Chromium, an Affymetrix GeneChip Analysis System, an Agilent scanner/microarray system, and an Illumina HiScan system. These instruments enable a wide range of genetic, epigenetic, and gene expression analysis capabilities (whole genome and exome sequencing and microarray), miRNA expression (miRNA-seq and miRNA arrays), SNP/indel and copy number variation (whole genome and targeted DNA-seq, copy number arrays), protein and DNA/RNA interaction (ChIP-seq and RIP-seq), DNA methylation (BS-seq and RRBS-seq, EPIC methylation array), genome-wide and custom genotyping (SNP arrays), and single cell transcriptomics. The core also has an ABI ViiA 7 Taqman Real-time PCR system, an excellent technology for library quantification and expression validation, as well as a Nanodrop, Qubit, and Agilent Bioanalyzer for sample QC. The IGBC recently launched several new services, including single cell RNA-seq and DNA-seq using a Fluidigm C1 Single Cell Prep System; BCR/TCR sequencing and microbiome profiling using miSeq; and base modification detection, Iso-Seq analysis, and de novo assembly of small to intermediate genomes using a PacBio RSII. These new services have enabled COHCCC members to expand the nature, depth, and scope of their genomic investigations. The core is co-directed by Drs. Xiwei Wu and Yate-Ching Yuan, with oversight by an interdisciplinary faculty Advisory Committee. User feedback is provided annually through user surveys. Since the last competitive renewal the IGBC contributed to 135 publications by COHCCC members. Over the past five years, the IGBC was used by 146 investigators, including 100 CC members representing all five Programs. Of the 100 CC members, 81 (81%) had peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059198
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394

Showing the most recent 10 out of 1396 publications